REGENERON PHARMACEUTICALS ($REGN) posted quarterly earnings results on Friday, August 1st. The company reported earnings of $12.89 per share, beating estimates of $8.61 by $4.28. The company also reported revenue of $3,675,600,000, beating estimates of $3,351,180,522 by $324,419,478.
You can see Quiver Quantitative's $REGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
REGENERON PHARMACEUTICALS Hedge Fund Activity
We have seen 606 institutional investors add shares of REGENERON PHARMACEUTICALS stock to their portfolio, and 661 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO removed 1,401,174 shares (-19.8%) from their portfolio in Q1 2025, for an estimated $888,666,586
- CAPITAL WORLD INVESTORS removed 840,346 shares (-30.2%) from their portfolio in Q1 2025, for an estimated $532,972,643
- GAMMA INVESTING LLC removed 814,345 shares (-99.8%) from their portfolio in Q2 2025, for an estimated $427,531,125
- CAPITAL INTERNATIONAL INVESTORS removed 747,797 shares (-15.8%) from their portfolio in Q1 2025, for an estimated $474,275,291
- FMR LLC removed 600,995 shares (-7.3%) from their portfolio in Q1 2025, for an estimated $381,169,058
- TWO SIGMA ADVISERS, LP added 553,800 shares (+inf%) to their portfolio in Q1 2025, for an estimated $351,236,574
- GOLDMAN SACHS GROUP INC added 498,456 shares (+77.3%) to their portfolio in Q1 2025, for an estimated $316,135,748
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
REGENERON PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $REGN stock 8 times in the past 6 months. Of those trades, 1 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $REGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN has traded it 3 times. They made 1 purchase worth up to $15,000 on 05/15 and 2 sales worth up to $30,000 on 04/08, 02/25.
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 04/10.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 04/07.
- REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 04/01, 02/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
REGENERON PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $REGN in the last several months. We have seen 12 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 07/23/2025
- JP Morgan issued a "Overweight" rating on 06/09/2025
- Citigroup issued a "Buy" rating on 06/02/2025
- BMO Capital issued a "Outperform" rating on 06/02/2025
- Morgan Stanley issued a "Overweight" rating on 06/02/2025
- RBC Capital issued a "Outperform" rating on 05/27/2025
- Guggenheim issued a "Buy" rating on 05/01/2025
To track analyst ratings and price targets for REGENERON PHARMACEUTICALS, check out Quiver Quantitative's $REGN forecast page.
REGENERON PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $REGN recently. We have seen 16 analysts offer price targets for $REGN in the last 6 months, with a median target of $777.0.
Here are some recent targets:
- John Newman from Canaccord Genuity set a target price of $850.0 on 07/23/2025
- Trung Huynh from UBS set a target price of $584.0 on 07/11/2025
- Matthew Harrison from Morgan Stanley set a target price of $754.0 on 07/10/2025
- Chris Schott from JP Morgan set a target price of $800.0 on 06/09/2025
- Geoff Meacham from Citigroup set a target price of $650.0 on 06/02/2025
- Evan David Seigerman from BMO Capital set a target price of $600.0 on 06/02/2025
- Mohit Bansal from Wells Fargo set a target price of $580.0 on 05/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
